Form 4: Artiva CEO Aslan Reports RSU Grant, Tax Withholding

Artiva Biotherapeutics' President and CEO, Fred Aslan, reported the acquisition of 366,850 restricted stock units and the disposition of 14,600 shares for tax obligations.

Summary

• Fred Aslan, President and CEO, and a Director of Artiva Biotherapeutics, Inc. (ARTV), reported changes in his beneficial ownership.
• On February 15, 2026, Aslan acquired 366,850 shares of common stock through a restricted stock unit (RSU) award.
• This RSU award was granted under the Issuer's 2024 Equity Incentive Plan at a price of $0 per share.
• Concurrently, on February 15, 2026, Aslan disposed of 14,600 shares of common stock at a price of $4 per share.
• This disposition was to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
• Following these transactions, Aslan's direct beneficial ownership stands at 1,562,198 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The RSU grant is a positive for executive incentive alignment, while the share disposition for tax purposes is a routine, non-discretionary event.

Positives

• The grant of 366,850 restricted stock units aligns executive incentives with long-term shareholder value creation.

Negatives

• The disposition of 14,600 shares, while for tax purposes, represents a reduction in direct ownership.

Industry Context

StockSavvy.ai notes that restricted stock unit grants are a common form of executive compensation in the biotechnology industry, designed to incentivize long-term performance and align management interests with those of shareholders. The associated tax withholding is a standard practice upon RSU vesting.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with long-term company performance, potentially benefiting shareholders through sustained growth and value creation.

Key Dates

Recommendation

This Form 4 details routine compensation and tax-related share dispositions by an insider, which does not fundamentally alter the investment thesis for Artiva Biotherapeutics. It provides transparency on executive ownership but does not present new information warranting a change in investment recommendation.

Keywords

Artiva Biotherapeutics, ARTV, Fred Aslan, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Incentive Plan, Biotechnology